Skip to main
CTSO

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp has reported a 10% increase in product revenues year-over-year, reaching $9.5 million, with gross margins exceeding 70%, reflecting improved geographic mix and manufacturing efficiencies. The company has demonstrated significant growth in global distributor sales, which rose 14.4% year-over-year, while direct sales outside Germany experienced a robust 23.5% increase. Additionally, advancements in the DrugSorb ATR product and supportive clinical publications bolster the company's outlook by enhancing its evidence base and market potential.

Bears say

CytoSorbents Corp's revenue projections have been revised downward for both 2025 and 2026, reflecting ongoing challenges in commercial sales within Germany, which is critical to the company's revenue growth. The negative outlook is further exacerbated by management's indication of patient imbalances in the initial U.S. commercial launch, which raises concerns about market acceptance and sales performance. Additionally, despite a distressed valuation that seems detached from fundamentals, the company's financial forecasts suggest potential difficulties in attaining growth targets amid a constrained revenue environment.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.